Startseite Second-trimester maternal serum markers in the prediction of preeclampsia
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Second-trimester maternal serum markers in the prediction of preeclampsia

  • Qiong Luo und Xiujun Han EMAIL logo
Veröffentlicht/Copyright: 9. Dezember 2016
Journal of Perinatal Medicine
Aus der Zeitschrift Journal of Perinatal Medicine Band 45 Heft 7

Abstract

Aim:

To determine whether late second-trimester maternal serum biomarkers are useful for the prediction of preeclampsia during the third trimester, a case-control study including 33 preeclamptic and 71 healthy pregnancies was conducted. Maternal serum concentrations of placental protein 13 (PP13), pregnancy-associated plasma protein (PAPP-A), pentraxin3 (PTX3), soluble FMS-like tyrosine kinase-1 (sFlt-1), myostatin and follistatin-like-3 (FSLT-3) were measured at 24–28 weeks’ gestation. All the concentrations of these markers were compared between the preeclamptic and control groups. Receiver operating characteristic (ROC) curve analysis was applied to assess sensitivity and specificity of serum markers with significant difference.

Results:

The levels of PP13 and sFlt-1 were significantly increased and FSLT3 was significantly decreased in patients with preeclampsia. However, the concentration of PAPPA, PTX3 and myostatin did not differ significantly. In screening for preeclampsia during the third trimester by PP13, sFlt-1 and FSLT3, the detection rate was 61.3%, 48.1% and 39.1%, respectively, at 80% specificity, and the detection rate increased to 69.8% by combination of these three markers.

Conclusion:

Maternal serum levels of PP13, sFlt-1 and FSLT3 play an important role in predicting late-onset preeclampsia, and the combination of these three markers significantly increases the detection rate for prediction.

Keywords: Late-onset preeclampsia; prediction; second trimester; serum biomarkers

Funding source: National Natural Science Foundation of China

Award Identifier / Grant number: 81571447

Funding statement: Funding: The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: National Natural Science Foundation of China (NO. 81571447).

Author’s statement

  1. Conflict of interest: Authors state no conflict of interest.

  2. Material and methods: Informed consent: Informed consent has been obtained from all individuals included in this study.

  3. Ethical approval: The research related to human subject use has complied with all the relevant national regulations, and institutional policies, and is in accordance with the tenets of the Helsinki Declaration, and has been approved by the authors’ institutional review board or equivalent committee.

References

[1] Brown MA, Lindheimer MD, Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Preg. 2001;20:IX–XIV.10.3109/10641950109152635Suche in Google Scholar

[2] Pérez-Sepúlveda A, Torres MJ, Valenzuela FJ, Larraín R, Figueroa-Diesel H, Galaz J, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004;89:770–5.10.1210/jc.2003-031244Suche in Google Scholar PubMed

[3] Kuc S, Wortelboer EJ, van Rijn BB, Franx A, Visser GH, Schielen PC. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv. 2011;66:225–39.10.1097/OGX.0b013e3182227027Suche in Google Scholar PubMed

[4] Sado T, Naruse K, Noguchi T, Haruta S, Yoshida S, Tanase Y, et al. Inflammatory pattern recognition receptors and their ligands: factors contributing to the pathogenesis of preeclampsia. Inflamm Res. 2011;60:509–20.10.1007/s00011-011-0319-4Suche in Google Scholar PubMed PubMed Central

[5] Romero R, Kusanovic JP, Than NG, Erez O, Gotsch F, Espinoza J, et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol. 2008;199:122.e1–11.10.1016/j.ajog.2008.01.013Suche in Google Scholar PubMed PubMed Central

[6] Lehnen H, Mosblech N, Reineke T, Puchooa A, Menke-Möllers I, Zechner U, et al. Prenatal clinical assessment of sFlt-1 (soluble fms-like tyrosine kinase-1)/PlGF (placental growth factor) ratio as a diagnostic tool for preeclampsia, pregnancy-induced hypertension, and proteinuria. Geburtshilfe Frauenheilkd. 2013;73:440–5.10.1055/s-0032-1328601Suche in Google Scholar PubMed PubMed Central

[7] Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63:346–52.10.1161/HYPERTENSIONAHA.113.01787Suche in Google Scholar PubMed

[8] Scazzocchio E, Figueras F, Crispi F, Meler E, Masoller N, Mula R, et al. Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. Am J Obstet Gynecol. 2013;208:203.e1–210.10.1016/j.ajog.2012.12.016Suche in Google Scholar PubMed

[9] Giguère Y, Charland M, Thériault S, Bujold E, Laroche M, Rousseau F, et al. Linking preeclampsia and cardiovascular disease later in life. Clin Chem Lab Med. 2012;50:985–93.10.1515/cclm.2011.764Suche in Google Scholar PubMed

[10] Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Is serum placental growth factor more effective as a biomarker in predicting early onset preeclampsia in early second trimester than in first trimester of pregnancy? Arch Gynecol Obstet. 2013;287:865–73.10.1007/s00404-012-2662-2Suche in Google Scholar PubMed

[11] Hu D, Tian T, Guo J, Wang H, Chen D, Dong M. Decreased maternal and placental concentrations of follistatin-like 3 in gestational diabetes. Clin Chim Acta. 2012;413:533–6.10.1016/j.cca.2011.10.029Suche in Google Scholar PubMed

[12] Chaiworapongsa T, Romero R, Korzeniewski SJ, Kusanovic JP, Soto E, Lam J, et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol. 2013;208:287.e1–15.10.1016/j.ajog.2013.01.016Suche in Google Scholar PubMed PubMed Central

[13] Ree PH, Hahn WB, Chang SW, Jung SH, Kang JH, Cha DH, et al. Early detection of preeclampsia using inhibin a and other second-trimester serum markers. Fetal Diagn Ther. 201;29:280–6.10.1159/000322742Suche in Google Scholar PubMed

[14] Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Can maternal serum placental growth factor estimation in early second trimester predict the occurrence of early onset preeclampsia and/or early onset intrauterine growth restriction? A prospective cohort study. J Obstet Gynaecol Res. 2013;39:881–90.10.1111/jog.12006Suche in Google Scholar PubMed

[15] Than NG, Pick E, Bellyei S, Szigeti A, Burger O, Berente Z, et al. Functional analyses of placental protein 13/galectin-13. Eur J Biochem. 2004;271:1065–78.10.1111/j.1432-1033.2004.04004.xSuche in Google Scholar PubMed

[16] Wortelboer EJ, Koster MP, Cuckle HS, Stoutenbeek PH, Schielen PC, Visser GH. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset preeclampsia. Br J Obstet Gynaecol. 2010;117:1384–89.10.1111/j.1471-0528.2010.02690.xSuche in Google Scholar PubMed

[17] Burger O, Pick E, Zwickel J, Klayman M, Meiri H, Slotky R, et al. Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta. 2004;25:608–22.10.1016/j.placenta.2003.12.009Suche in Google Scholar PubMed

[18] Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol. 2006;27:13–7.10.1002/uog.2686Suche in Google Scholar PubMed

[19] Guibourdenche J, Frendo JL, Pidoux G, Bertin G, Luton D, Muller F, et al. Expression of pregnancy-associated plasma protein-A (PAPP-A) during human villous trophoblast differentiation in vitro. Placenta. 2003;24:532–9.10.1053/plac.2002.0944Suche in Google Scholar PubMed

[20] Irwin JC, Suen LF, Martina NA, Mark SP, Giudice LC. Role of the IGF system in trophoblast invasion and preeclampsia. Hum Reprod. 1999;14:90–6.10.1093/humrep/14.suppl_2.90Suche in Google Scholar PubMed

[21] Hughes G, Bischof P, Wilson G, Smith R, Klopper A. Assay of placental protein to determine fetal risk. Br Med J. 1980;280:671–3.10.1136/bmj.280.6215.671Suche in Google Scholar PubMed PubMed Central

[22] Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002;87:1762–7.10.1210/jcem.87.4.8430Suche in Google Scholar PubMed

[23] Bersinger NA, Odegard RA. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand. 2004;83:37–45.10.1111/j.1600-0412.2004.00277.xSuche in Google Scholar PubMed

[24] Bersinger NA, Smarason AK, Muttukrishna S, Groome NP, Redman CW. Women with pre-eclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A,activin A and soluble E-selectin. Hypertens Preg. 2003;22:45–55.10.1081/PRG-120016794Suche in Google Scholar PubMed

[25] Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factor and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol 1993;150:1804–12.10.4049/jimmunol.150.5.1804Suche in Google Scholar PubMed

[26] Rovere-Querini P, Antonacci S, Dell’Antonio G, Angeli A, Almirante G, Cin ED, et al. Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia. Obstet Gynecol. 2006;108:148–55.10.1097/01.AOG.0000224607.46622.bcSuche in Google Scholar PubMed

[27] Al-Ramadi BK, Ellis M, Pasqualini F, Mantovani A. Selective induction of pentraxin 3, a soluble innate immune pattern recognition receptor, in infectious episodes in patients with haematological malignancy. Clin Immunol. 2004;112:221–4.10.1016/j.clim.2004.03.012Suche in Google Scholar PubMed

[28] Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition and female fertility. Annu Rev Immunol. 2005;23:337–66.10.1146/annurev.immunol.23.021704.115756Suche in Google Scholar PubMed

[29] Sado T, Naruse K, Noguchi T, Haruta S, Yoshida S, Tanase Y, et al. Inflammatory pattern recognition receptors and their ligands: factors contributing to the pathogenesis of preeclampsia. Inflamm Res. 2011;60:509–20.10.1007/s00011-011-0319-4Suche in Google Scholar PubMed PubMed Central

[30] Rovere-Querini P, Antonacci S, Dell’Antonio G, Angeli A, Almirante G, Cin ED, et al. Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia. Obstet Gynecol. 2006;108:148–55.10.1097/01.AOG.0000224607.46622.bcSuche in Google Scholar

[31] Larsson A, Palm M, Helmersson J, Axelsson O. Pentraxin 3 values during normal pregnancy. Inflammation. 2011;34:448–52.10.1007/s10753-010-9252-xSuche in Google Scholar PubMed

[32] Akolekar R, Casagrandi D, Livanos P, Tetteh A, Nicolaides KH. Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn. 2009;29:934–8.10.1002/pd.2311Suche in Google Scholar PubMed

[33] Cetin I, Cozzi V, Pasqualini F, Nebuloni M, Garlanda C, Vago L, et al. Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2006;194:1347–53.10.1016/j.ajog.2005.11.018Suche in Google Scholar PubMed

[34] Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol. 1998;16:5–15.10.1055/s-2007-1016248Suche in Google Scholar PubMed

[35] Cohen A, Lim KH, Lee Y, Rana S, Karumanchi SA, Brown F. Circulating levels of the antiangiogenic marker soluble FMS like tyrosine kinase 1 are elevated in women with pregestational diabetes and preeclampsia: angiogenic markers in preeclampsia and preexisting diabetes. Diabetes Care. 2007;30:375–7.10.2337/dc06-1514Suche in Google Scholar PubMed

[36] Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–83.10.1056/NEJMoa031884Suche in Google Scholar PubMed

[37] Shokry M, Bedaiwy MA, Fathalla MM, Alsemary A, Elwakil S, Murphy A. Maternal serum placental growth factor and soluble fms-like tyrosine kinase 1 as early predictors of preeclampsia. Acta Obstet Gynecol Scand. 2010;89:143–6.10.3109/00016340903289892Suche in Google Scholar PubMed

[38] Shokry M, Bedaiwy MA, Fathalla MM, Alsemary A, Elwakil S, Murphy A. Maternal serum placental growth factor and soluble fms-like tyrosine kinase 1 as early predictors of preeclampsia. Acta Obstet Gynecol Scand. 2010;89:143–6.10.3109/00016340903289892Suche in Google Scholar PubMed

[39] Peiris HN, Ponnampalam AP, Osepchook CC, Mitchell MD, Green MP. Placental expression of myostatin and follistatin-like-3 protein in a model of developmental programming. Am J Physiol Endocrinol Metab. 2010;298:E854–61.10.1152/ajpendo.00673.2009Suche in Google Scholar PubMed

[40] Zheng YL, Ma HM, Zheng YM, Wang YS, Zhang BW, He XY, et al. Site-directed mutagenesis of the myostatin gene in ovine fetal myoblast cells in vitro. Res Vet Sci. 2012;93:763–9.10.1016/j.rvsc.2011.10.022Suche in Google Scholar PubMed

[41] Mitchell MD, Osepchook CC, Leung KC, McMahon CD, Bass JJ. Myostatin is a human placental product that regulates glucose uptake. J Clin Endocrinol Metab. 2006;91:1434–7.10.1210/jc.2005-2361Suche in Google Scholar PubMed

[42] Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology. 2006;147:3586–97.10.1210/en.2006-0089Suche in Google Scholar PubMed

[43] Peiris HN, Lappas M, Georgiou HM, Vaswani K, Salomon C, Rice GE, et al. Myostatin in the placentae of pregnancies complicated with gestational diabetes mellitus. Placenta. 2015;36:1–6.10.1016/j.placenta.2014.11.006Suche in Google Scholar PubMed

[44] Robertson RD, Mukherjee A. Synexpression group analyses identify new functions of FSTL3, a TGFβ ligand inhibitor. Biochem Biophys Res Commun. 2012;427:568–73.10.1016/j.bbrc.2012.09.098Suche in Google Scholar PubMed

[45] Okamoto A, Endo H, Kalionis B, Shinya M, Saito M, Nikaido T, et al. IGFBP1 and follistatin-like 3 genes are significantly up-regulated in expression profiles of the IUGR placenta. Placenta. 2006;27:317–21.10.1016/j.placenta.2004.12.007Suche in Google Scholar PubMed

[46] Biron-Shental T, Schaiff WT, Rimon E, Shim TL, Nelson DM, Sadovsky Y. Hypoxia enhances the expression of follistatin-like 3 in term human trophoblasts. Placenta. 2008;29:51–7.10.1016/j.placenta.2007.09.001Suche in Google Scholar PubMed PubMed Central

[47] Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig. 2004;11:342–52.10.1016/j.jsgi.2004.03.003Suche in Google Scholar PubMed

Received: 2016-7-27
Accepted: 2016-11-1
Published Online: 2016-12-9
Published in Print: 2017-10-26

©2017 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Preeclampsia and intrauterine growth restriction: placental disorders still not fully understood
  4. Review article
  5. Hepar uterinum: a history of ideas on fetal nutrition
  6. Original articles
  7. Twin pregnancy in women above the age of 45 years: maternal and neonatal outcomes
  8. Maternal endothelial damage as a disorder shared by early preeclampsia, late preeclampsia and intrauterine growth restriction
  9. Maternal venous SHARP1 levels in preeclampsia
  10. Second-trimester maternal serum markers in the prediction of preeclampsia
  11. Pregnancy outcomes regarding maternal serum AFP value in second trimester screening
  12. Quantification of mechanical dyssynchrony in growth restricted fetuses and normal controls using speckle tracking echocardiography (STE)
  13. Serum cholesterol acceptor capacity in intrauterine growth restricted fetuses
  14. Antithrombin improves the maternal and neonatal outcomes but not the angiogenic factors in extremely growth-restricted fetuses at <28 weeks of gestation
  15. Simple approach based on maternal characteristics and mean arterial pressure for the prediction of preeclampsia in the first trimester of pregnancy
  16. Fetal death: an extreme manifestation of maternal anti-fetal rejection
  17. Intrauterine growth restriction and placental gene expression in severe preeclampsia, comparing early-onset and late-onset forms
  18. The relationship between maternal and umbilical cord adropin levels with the presence and severity of preeclampsia
  19. Expression of placental regulatory genes is associated with fetal growth
  20. Circulating soluble fms-like tyrosine kinase-1 and placental growth factor from 10 to 40 weeks’ pregnancy in normotensive women
  21. A one year review of eclampsia in an Ethiopian Tertiary Care Center (Saint Paul’s Hospital Millennium Medical College, SPHMMC)
  22. Congress Calendar
  23. Congress Calendar
https://doi.org/10.1515/jpm-2016-0249
Schlagwörter für diesen Artikel
Late-onset preeclampsia; prediction; second trimester; serum biomarkers

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Preeclampsia and intrauterine growth restriction: placental disorders still not fully understood
  4. Review article
  5. Hepar uterinum: a history of ideas on fetal nutrition
  6. Original articles
  7. Twin pregnancy in women above the age of 45 years: maternal and neonatal outcomes
  8. Maternal endothelial damage as a disorder shared by early preeclampsia, late preeclampsia and intrauterine growth restriction
  9. Maternal venous SHARP1 levels in preeclampsia
  10. Second-trimester maternal serum markers in the prediction of preeclampsia
  11. Pregnancy outcomes regarding maternal serum AFP value in second trimester screening
  12. Quantification of mechanical dyssynchrony in growth restricted fetuses and normal controls using speckle tracking echocardiography (STE)
  13. Serum cholesterol acceptor capacity in intrauterine growth restricted fetuses
  14. Antithrombin improves the maternal and neonatal outcomes but not the angiogenic factors in extremely growth-restricted fetuses at <28 weeks of gestation
  15. Simple approach based on maternal characteristics and mean arterial pressure for the prediction of preeclampsia in the first trimester of pregnancy
  16. Fetal death: an extreme manifestation of maternal anti-fetal rejection
  17. Intrauterine growth restriction and placental gene expression in severe preeclampsia, comparing early-onset and late-onset forms
  18. The relationship between maternal and umbilical cord adropin levels with the presence and severity of preeclampsia
  19. Expression of placental regulatory genes is associated with fetal growth
  20. Circulating soluble fms-like tyrosine kinase-1 and placental growth factor from 10 to 40 weeks’ pregnancy in normotensive women
  21. A one year review of eclampsia in an Ethiopian Tertiary Care Center (Saint Paul’s Hospital Millennium Medical College, SPHMMC)
  22. Congress Calendar
  23. Congress Calendar
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 21.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpm-2016-0249/html
Button zum nach oben scrollen